Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses. Hong Kong SAR, China, 24-26 January 2013.

Vaccine

Volumn 31, Issue 37, 2013, Pages 3766-3771

  Girard, Marc P ^a   Tam, John S ^b   Pervikov, Yuri ^b   Katz, Jacqueline M ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adjuvants; Inactivated influenza vaccines; Live attenuated influenza vaccines; Neutralizing antibodies; Pandemic influenza vaccines; Seasonal influenza vaccines; Universal influenza vaccines

Indexed keywords

ADJUVANT; EPITOPE; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; TRIVALENT INACTIVATED VACCINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

CELLULAR IMMUNITY; CHILDHOOD DISEASE; CLINICAL EVALUATION; CONFERENCE PAPER; CROSS PROTECTION; CROSS REACTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; NARCOLEPSY; NONHUMAN; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; SEROCONVERSION; VIRUS LIKE AGENT; WORLD HEALTH ORGANIZATION;

ADJUVANTS; INACTIVATED INFLUENZA VACCINES; LIVE ATTENUATED INFLUENZA VACCINES; NEUTRALIZING ANTIBODIES; PANDEMIC INFLUENZA VACCINES; SEASONAL INFLUENZA VACCINES; UNIVERSAL INFLUENZA VACCINES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINATION; VACCINES, ATTENUATED; WORLD HEALTH ORGANIZATION;

EID: 84881546964     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.047     Document Type: Conference Paper

References (70)

1. Vaccines against influenza WHO position paper-November 2012. Weekly Epidem Rec 2012, 87:461-476.
2. Kaur K., Sullivan M., Wilson P.C. Targeting B cell responses in universal influenza vaccine design. Trends Immunol 2011, 32:524-531.
3. Shaw A. New technologies for new influenza vaccines. Vaccine 2012, 30:4927-4933.
4. Pica N., Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
5. Fiers W., De Filette M., El Bakkouri K., Scheppens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
6. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
7. Jegaskanda S., Job E.R., Kramski M., Laurie K., Isitman G., de Rose R., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013, 190:1837-1848.
8. Hu H., Voss J., Zhang G., Buchy P., Zuo T., Wang L., et al. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. J Virol 2012, 86:2978-2989.
9. Qian M., Hu H., Zuo T., Wang G., Zhang L., Zhou P. Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. J Virol 2013, 87:3571-3577.
10. Du L., Jin L., Zhao G., Sun S., Li J., Yu K., et al. Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin. J Virol 2013, 87:2215-2225.
11. Giles B.M., Crevar C.J., Carter D.M., Bissel S.J., Schultz-Cherry S., Wiley C.A., et al. A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 2012, 205:1562-1570.
12. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen M.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
13. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333:843-850.
14. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
15. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 2010, 6(2):e1000796.
16. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza hemagglutinins. Science 2011, 333:850-856.
17. Dreyfus C., Ekiert D.C., Wilson I.A. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J Virol 2013, 87:7149-7154.
18. Dreyfus C., Laursen N.S., Kwaks T., Zuijdgeest D., Khayat R., Ekiert D.C., et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337:1343-1348.
19. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010, 107:18979-18984.
20. Lingwood D., Mc Tamney P.M., Yassine H.M., Whittle J.R., Guo X., Boyington J.C., et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 2012, 489:566-570.
21. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1:1-10.
22. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidesker J.G., Najar T.A., et al. Design of a HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 2010, 107:13701-13706.
23. Krammer F., Pica N., Hai R., Margine I., Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013, 87:6542-6550.
24. Easterbrook J.D., Schwartzman L.M., Gao J., Kash J.C., Morens D.M., Couzens L., et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing pandemic H1N1 neuraminidase in mice. Virology 2012, 432:39-44.
25. Wu C.Y., Yeh Y.C., Chan J.T., Yang Y.C., Yang J.R., Liu M.T., et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS ONE 2012, 7:e42363.
26. Rockman S., Brown L.E., Barr I.G., Gilbertson B., Lowther S., Kachurin A., et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza in ferrets immunized with seasonal influenza vaccine. J Virol 2013, 87:3053-3061.
27. Hillaire M.L., van Trierum S.E., Kreijtz J.H., Bodewes R., Geelhoed-Mieras M.M., Nieuwkoop N.J., et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011, 92:2339-2349.
28. Weinfurter J.T., Brunner K., Capuano S.V., Li C., Broman K.W., Kawaoka Y., et al. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 2011, 7:e1002381.
29. + T cell response following infection with 2009 pandemic influenza H1N1 virus. J Virol 2011, 85:12057-12061.
30. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280.
31. Kreijtz J.H., de Mutsert G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008, 82:5161-5166.
32. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
33. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55:19-25.
34. Pleguezuelos O., Robinson S., Stoloff G.A., Caparros-Wanderley W. Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 2012, 30:4655-4660.
35. Ambrose C.S., Dubovsky F., Belshe R.B., Ashkenazi S. The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. Eur J Clin Microbiol Infect Dis 2012, 31:2549-2557.
36. Ambrose C.S., Wu X. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine 2013, 31:857-860.
37. Karron R.A., Talaat K., Luke C., Callahan K., Thumar B., DiLorenzo S.C., et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009, 27:4953-4960.
38. Karron R.A., Callahan K., Luke C., Thumar B., McAuliffe J., Schappel E., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009, 199:711-716.
39. Talaat K.R., Karron R.A., Callahan K.A., Luke C.J., DiLorenzo S.C., Chen G.L., et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
40. Kang S.M., Kim M.C., Compans R.W. Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012, 11:995-1007.
41. Lei H., Xu Y., Chen J., Wei X., Lam D.M. Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules. Virology 2010, 407:319-324.
42. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009, 200:172-180.
43. DiazGranados C.A., Dunning A.J., Jordanov E., Landolfi V., Denis M., Talbot H.K. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013, 31:861-866.
44. Ansaldi F., Durando P., Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin Biol Ther 2011, 11:415-427.
45. (®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012, 30:2908-2913.
46. Belshe R.B. The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010, 28(Suppl. 4):D45-D53.
47. Block S.L., Yi T., Sheldon E., Dubovsky F., Falloon J. A randomized, double-blind, non inferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine 2011, 29:9391-9397.
48. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Deaker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31:770-776.
49. Barrett P.N., Berezuk G., Fritsch S. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2011, 377:751-759.
50. Ehrlich H.J., Singer J., Berezuk G., Fritsch S., Aichinger G., Hart M.K., et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis 2012, 54:946-954.
51. Frey S., Vesikari T., Szymczakiewicz-Multanowska A., Lattanzi M., Groth N., Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010, 51:997-1004.
52. Ehrlich H.J., Müller M., Oh H.M., Tambuah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
53. Ehrlich H.J., Müller M., Fritsch S., Zeitlinger M., Berezuk G., Löw-Baselli A., et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.
54. Ansaldi F., Zancolli M., Durando P., Montomoli E., Sticchi L., Del Giudice G., et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strains and clinical isolates. Vaccine 2010, 28:4123-4129.
55. Vesikari T., Knuf M., Wutzier P., Karvonen A., Kieninger-Baum D., Scmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
56. Mannino S., Villa M., Apolone G., Weiss N.S., Groth N., Aquino I., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012, 176:527-533.
57. Madhun A.S., Haaheim L.R., Nilsen M.V., Cox R.J. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 2009, 27:7367-7376.
58. Cox R.J., Pedersen G., Madhun A.S., Svindland S., Salvik M., Breakwell L., et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011, 29:8049-8059.
59. Pedersen G.K., Madhun A.S., Breakwell Hoschler K., Sjursen H., Pathirana R.D., et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012, 206:158-166.
60. Zaman K., Roy E., Arifeen S.E., Rahman M., Raqib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1555-1564.
61. Ortiz J.R., Englund J.A., Neuzil K.M. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011, 29:4439-4452.
62. Oppermann M., Fritzsche J., Weber-Schoendorfer C., Keller-Stanislawski B., Allignol A., et al. A(H1N1)v2009: a controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012, 30:4445-4452.
63. Pasternak B., Svanström H., Molgaard-Nielsen D., Krause T.G., Emborg H.D., Melbye M., et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012, 344:e2794.
64. Esposito S., Gasparini C., Martelli A., Zenga A., Tremolati E., Varin E., et al. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008, 26:4664-4668.
65. Miller E., Andrews N., Stellitano L., Stowe J., Winstone A.M., Schneerson J., et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:1794.
66. Archer B., Cohen C., Naidoo D., Thomas J., Makunga C., Blumberg L., et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009, 14:19369.
67. Cohen C., Simonsen L., Sample J., Kang J.W., Miller M., Madhi S.A., et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012, 55:996-1003.
68. McKittrick N., Frank I., Jacobson J.M., White C.J., Kim D., Kappes R., et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013, 158:19-26.
69. El Sahly H.M., Davis C., Kotloff K., Meier J., Winokur P.L., Wald A., et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis 2012, 205:703-712.
70. Madhi S.A., Dittmer S., Kuwanda L., Venter M., Cassim H., Lazarus E., et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. AIDS 2013, 27:369-379.